Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older (male or female)
- People with a laboratory-confirmed diagnosis of clear cell renal cell carcinoma (a specific type of kidney cancer) that has spread, cannot be surgically removed, or is advanced — and where all standard treatments have already been tried
- People whose cancer can be measured and tracked using standard imaging guidelines
- People whose tumour shows a specific biological marker detected during screening (confirm with trial site)
- People who are largely able to carry out daily activities, with little to no limitation due to their illness (confirm with trial site)
- People whose organs such as the liver, kidneys, and bone marrow are functioning at an adequate level
- People expected to live for at least 12 weeks, as assessed by the treating doctor
Who may not be able to join:
- People with serious, uncontrolled medical conditions or other life-threatening health problems alongside their cancer
- People who have received chemotherapy, radiation, immunotherapy, major surgery, or any other cancer treatment within the past 28 days
- People who still have significant side effects from a previous cancer treatment, surgery, or radiotherapy that have not resolved
- People who have received a radioactive drug used for treatment purposes within the past 6 months
- People who have previously received any treatment that targets a protein called CA9
- People with a known allergy or sensitivity to the trial drugs or any of their ingredients
- People with unstable brain or central nervous system tumours at the time of screening
- People with a history of bowel perforation, bowel infarction, active stomach or duodenal ulcers, fistulas, severe reflux disease, severe bowel inflammation, or unresolved radiation injury to the digestive tract within the past 2 years
- People who have had a serious infection requiring intravenous antibiotics, antivirals, or antifungal medications within the 14 days before starting treatment
- People who are pregnant or breastfeeding
- People with a known active HIV, hepatitis B, or hepatitis C infection
- People who have been diagnosed with another separate primary cancer
- People with significant or uncontrolled heart or cardiovascular disease
- People with a blockage in urinary flow or urinary incontinence that cannot be managed
- People with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis
- People who have had major surgery within 12 weeks before enrolling
- People with a history of psychiatric illness or personal circumstances that may make it difficult to follow the trial requirements or to provide informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 044-270-1300
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number and proportion of participants who experience at least 1 dose-limiting toxicities (DLTs).; Incidence, intensity, seriousness, and causality of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse event of special interest (AESI) and serious adverse events (SAEs).; Incidence of TEAEs leading to dose delay, dose interruption, dose reduction, and/or discontinuation.; Maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of PD-32766T based on dose-limiting toxicities.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.